TRACON Pharmaceuticals WKN: A2PU7C ISIN: US89237H2094 Forum: Aktien Thema: Hauptdiskussion

Cash: 19.1mio$ Burn: 2.2mio$/month finanziert bis Mai 2020

TRACON Pharmaceuticals, 3D Medicines And Jiangsu Alphamab Announce Partnership For Development Of Subcutaneous PD-L1 Single-Domain Antibody In Soft Tissue Sarcoma Company to Host Investor Conference Call Today at 8:30 a.m. ET / 5:30 a.m. PT Envafolimab represents a potential best-in-class PD-L1 inhibitor that is injectable subcutaneously without the need for an adjuvant Envafolimab has been dosed in more than 650 patients in the U.S., China and Japan, and is currently being evaluated in registrational trials in China in patients with high microsatellite instability (“MSI-H”) cancer and biliary tract cancer Immune checkpoint inhibitors targeting the PD-1 or PD-L1 pathway have demonstrated activity in multiple soft tissue sarcoma subtypes, including undifferentiated pleomorphic sarcoma (UPS) TRACON intends to initiate a registration enabling study of envafolimab in the sarcoma subtype of UPS in 2020 https://traconpharma.gcs-web.com/news-releases/news-release-details/tracon-pharmaceuticals-3d-medicines-and-jiangsu-alphamab

WL